ERBB2 and breast cancer: While there was significant benefit from chemotherapy on DFS in both the subgroups with basal-like and luminal B subtype breast cancer, there was no effect in women with Her2-enriched tumors, and a less pronounced effect in those with luminal A tumors (Padjusted = 0.001).